Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NBIP-01435 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1: NBIP-01435 | EXPERIMENTAL | Participants will receive NBIP-01435 administered once a week (QW) subcutaneously (SC) for a minimum of 8 weeks. |
| Part 2: NBIP-01435 | EXPERIMENTAL | Participants will receive NBIP-01435 administered SC for a minimum of 8 weeks. |
| Name | Type | Description |
|---|---|---|
| NBIP-01435 | DRUG | NBIP-01435 will be administered per schedule specified in the arm description. |
Key Inclusion Criteria: * Medically confirmed diagnosis of classic 21-hydroxylase deficiency (21-OHD) CAH, based on standard, medically accepted criteria. * Stable glucocorticoid (GC) dose regimen for classic CAH for a minimum of 30 days before screening. * If treated with fludrocortisone, the dose...
NBIP-01435 is an investigational small molecule developed by Neurocrine Biosciences, Inc. (ticker NBIX) for the treatment of classic congenital adrenal hyperplasia, an endocrine disorder. It is currently in Phase 2 clinical development and has not been approved by the FDA.
NBIP-01435 is being developed as a treatment for classic congenital adrenal hyperplasia in adults. It is an investigational therapy in Phase 2 testing, and its efficacy and safety in this indication have not yet been established through completed clinical trials.
NBIP-01435 targets CRF1, the corticotropin-releasing factor type 1 receptor. CRF1 is a receptor target, and NBIP-01435 is a small molecule designed to act on it. This receptor is the molecular target under investigation in its clinical program.
NBIP-01435 is being developed by Neurocrine Biosciences, Inc., which trades under the ticker NBIX. The company is the sponsor of the clinical program evaluating this small molecule in congenital adrenal hyperplasia.
NBIP-01435 is in Phase 2 clinical development. It is an investigational drug and is not FDA approved. The Phase 2 program is evaluating the drug in adult participants with classic congenital adrenal hyperplasia.
NBIP-01435 is being studied in one clinical trial, NCT07850739, titled a Phase 2 study of efficacy, safety, tolerability, and pharmacokinetics in adult participants with classic congenital adrenal hyperplasia. The trial is not yet recruiting, is controlled, and is planned to enroll 36 participants.